Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SK Biopharmaceuticals Co., Ltd

http://www.skbp.com

Latest From SK Biopharmaceuticals Co., Ltd

SK’s Antiepileptic Speeds Japan Entry Via $500m Ono Partnership

Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.

Deals Neurology

SK Bio's 2020 Plans Undeterred By Pandemic

The CEO of South Korea's SK Biopharmaceuticals talks about commercialization plans, strategy for epilepsy drug cenobamate and other pipeline assets and planned IPO.

South Korea Business Strategies

SK Biopharm’s Hefty IPO To Support Novel Anti-Epileptic, Pipeline

SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.

South Korea Financing

Finance Watch: VC Mega-Rounds For Machine Learning, CNS Disorders, Academic Discoveries

Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • SK Holdings
    • SK Life Science, Inc.
    • SK Biofarm Co., Ltd.
UsernamePublicRestriction

Register